Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07SMD
|
||||
| Former ID |
DIB002838
|
||||
| Drug Name |
Dual norepinephrine reuptake inhibitors/5-HT1A partial agonists
|
||||
| Synonyms |
Dual norepinephrine reuptake inhibitors/5-HT1A partial agonists (neuropsychiatric disorders); Dual norepinephrine reuptake inhibitors/5-HT1A partial agonists (neuropsychiatric disorders), Pfizer
|
||||
| Indication | Psychiatric disorder [ICD9: 290-319; ICD10:F01-F99] | Investigative | [1] | ||
| Company |
Pfizer Global Research & Development
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
C1C(CN1)Oc1c(Oc2c(cccc2F)Cl)cccc1F
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1A receptor | Target Info | Agonist | [2] | |
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists. Bioorg Med Chem Lett. 2011 Jan 15;21(2):865-8 | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.